Prof. Dr. med. Klaus Herrlinger - Gastroenterologie, Hamburg - Publikationen

Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF.
Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Therap 2001; 15: 363-369

Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K.
Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastro 2002; 97:377-381

Herrlinger KR, Fellermann K, Stange EF.
Lack of influence of nutritional status on pulmonary function in inflammatory bowel disease
Am J Gastro 2002; 97: 2920-2921

Herrlinger KR, Schwab M, Kreisel W, Fischer C, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Fellermann K, Greinwald R, Stange EF. 6-Thioguanine-efficacy and safety in chronic active Crohn`s disease. Aliment Pharmacol Therap 2003; 17: 503-508

Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF.
Remission maintenance by tioguanine in chronic active Crohn`s disease. Aliment Pharmacol Therap 2003; 17: 1459-1464

Herrlinger KR, Dittmann R, Weitz G, Wehkamp J, Ludwig D, Schwab M, Stange EF, Fellermann K. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
Inflamm Bowel Dis 2004; 10: 229-233

Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Schoelmerich J, Fleig W, Ruhl A, Reinshagen M, Stange EF and Schwab M. Thioguanine-nucleotide levels do not predict efficacy of 6-tioguanine therapy in Crohn`s disease. Aliment Pharmacol Therap 2004; 19:1269-76

Herrlinger KR, Borutta A, Meinhardt G, Stange EF, Fellermann K. Fatal staphyloccocal sepsis in Crohn`s disease after infliximab. Inflamm Bowel Dis 2004; 10:655-656

Herrlinger KR, Cummings JR, Barnardo CNM, Schwab M, Ahmad T and Jewell DP.
The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005; 15: 705-711

Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M and Stange EF.
Randomized double-blind controlled trial of subcutaneous recombinant human intereukin-11 versus prednisolone in active Crohn’s disease. Am J Gastro 2006; 101: 793-797

Herrlinger KR, Barthel DN, Schmidt KJ, Büning J, Barthel CS, Wehkamp J, Stange EF and Fellermann K. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther 2010; 31:1036-41

Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M and
Schaeffeler E. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011; 89:422-8

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis. 2013;7:636-43


Original papers with senior authorship

Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR. Azathioprine versus mesalamine for prevention of postoperative clinical relapse in Crohn’s disease patients at high risk: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59:752-9

Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis—a need for prophylaxis. J Crohns Colitis. 2010 Nov;4(5):606-9

Escher M, Kainikkara TM, Grabner A, Ott G, Stange EF, Herrlinger KR. Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection. Dtsch Med Wochenschr. 2012; 137:260-4


Original papers with co-autorship

Fellermann K, Rudolph B, Witthoft T, Herrlinger KR, Tronnier M, Ludwig D, Stange EF.
Sweet-Syndrom und Erythema nodosum bei steroidrefraktärer Colitis ulcerosa - erfolgreiche Behandlung mit Tacolimus. Med Klin 2001; 96: 105-108

Fellermann K, Herrlinger KR, Witthoeft T, Homann N, Ludwig D, Stange EF. Tacrolimus: A new immunosuppressant for steroid refractory inflammatory bowel disease. Transplant Proc 2001; 33:2247-2248

Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, Wohlschlager C, Feller AC, Stange EF, Fellermann K. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002; 47:1349-1355

Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschläger C, Feller AC, Stange EF. Human -defensin 2 but not -defensin 1 is expressed preferentielly in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 745-752

Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324

Wehkamp J, Schmidt K, Herrlinger KR, Baxmann S, Behling S, Wohlschläger C, Feller AC, Stange EF, Fellermann K. Defensin pattern in chronic gastritis - HBD-2 is differentially expressed with respect to Helicobacter pylori status. J Clin Pathol 2003; 56: 352-357

Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. Inducible and constitutive ß-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2003; 9: 215-223

Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaeffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroeder J, Bevins CL, Fellermann K and Stange EF.
NOD2 (CARD15) mutations in Crohn´s disease are associated with diminished mucosal -defensin expression. Gut 2004; 53:1658-1664

Dignass AU, Herrlinger K, Scholmerich J. Chronisch aktiver Verlauf. Z Gastroenterol 2004; 42: 1012-1006

Cummings RFC, Herrlinger KR, Gorard DA, McIntyre AS, Travis SPL, Jewell DP.
Oral methotrexate in ulcerative colitis. Aliment Pharmacol Therap 2005; 21:385-389

Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr 2007; 119: 519-26

Geiger C, Föller M, Herrlinger KR, Lang F. Azathioprine-induced suicidal erythrocyte death.
Inflamm Bowel Dis 2008; 14: 1027-1032

Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Häuser W, Herrlinger K, Höhne W, Koletzko S, Krieglstein CF, Kruis W, Matthes H, Moser G, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, Sido B, Siegmund B, Stallmach A, Bokemeyer B, Stange EF, Zeitz M. [Clinical practice guideline on diagnosis and treatment of Crohn's disease] Z Gastroenterol 2008; 46: 1094-146.

Koslowski MJ, Kübler I, Chamaillard M, Schaeffeler E, Reinisch W, Wang G, Beisner J, Teml A, Peyrin-Biroulet L, Winter S, Herrlinger KR, Rutgeerts P, Vermeire S, Cooney R, Fellermann K, Jewell D, Bevins CL, Schwab M, Stange EF, Wehkamp J. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One 2009; 4:e4496 (Epub)

Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, Griger J, Fritz P, Fellermann K, Schwab M, Wehkamp J, Stange EF. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009; 77: 84-94

Schmidt KJ, Fellermann K, Wellhöner P, Weitz G, Homann N, Herrlinger K, Lehnert H, Ludwig D, Büning J. Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease. Aliment Pharmacol Ther 2009; 29:1230-9

Kübler I, Koslowski MJ, Gersemann M, Fellermann K, Beisner J, Becker S, Rothfuss K, Herrlinger KR, Stange EF, Wehkamp J. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease. Aliment Pharmacol Ther 2009; 30: 621-33

Karner S, Shi S, Fischer C, Schaeffeler E, Neurath M, Herrlinger KR, Hofmann U, Schwab M.
Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes - novel targets for thiopurine therapy?
Ther Drug Monit 2010; 32:119-28

Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO).
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010; 4:63-101

German IBD Study Group- Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis. Dtsch Med Wochenschr. 2011; 136:939-43

Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol. 2011; 49:1276-341.

Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-36

Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis. 2013;19:590-8

Preiß JC, Bokemeyer B, Buhr HJ, Dignaß A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, Siegmund B, Stallmach A, Stange EF, Stein J, Hoffmann JC. [Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014]. Z Gastroenterol. 2014; 52:1431-84.

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)].
Rev Gastroenterol Mex. 2015; 80:74-106

Rathmayer M, Scheffer H, Braun M, Heinlein W, Akoglu B, Brechmann T, Gölder SK, Lankisch T, Messmann H, Schneider A, Wagner M, Fleßa S, Meier A, Lewerenz B, Gossner L, Faiss S, Toermer T, Werner T, Wilke MH, Lerch MM, Schepp W; DRG-Arbeitsgruppe und das Zeiterfassungsprojekt der DGVS (Autoren im Anhang). [Improvement of cost allocation in gastroenterology by introduction of a novel service catalogue covering the complete spectrum of endoscopic procedures]. Z Gastroenterol. 2015; 53:183-98


Scientific letters and comments

Herrlinger KR, Schwab M, Fellermann K, Stange EF. 6-Thioguanine-buried alive? Gastroenterology 2004; 126: 940-941

Herrlinger KR, Fellermann K, Stange EF. Tacrolimus - finally! Gut 2006; 55: 1224-5

Herrlinger KR, Stange EF. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 363:1086

Herrlinger K, Stange EF. Biologicals first-line in chronic inflammatory bowel disease? No.
Dtsch Med Wochenschr. 2011;136:1789

Herrlinger KR, Stange EF. The debated role for thiopurines in Crohn's disease. J Crohns Colitis. 2014;8:172-4.


Scientific reviews

Herrlinger K, Stange EF. Evidence-based immunosuppression with azathioprine in inflammatory bowel diseases. Med Klin 2000; 95: 201-206

Herrlinger KR, Stange EF. The pancreas and inflammatory bowel diseases. Intern J Pancreatol 2000; 27: 171-179

Herrlinger K, Fellermann K, Stange EF. Standard therapy of ulcerative colitis – evidence- and consenus-based recommendations. Internist 2002; 11: 1367-1375

Schwab M, Herrlinger K, Schaeffeler E, Stange EF. Clinical pharmacology of azathioprine, 6-mercaptopurine and 6-thioguanine in the treatment of inflammatory bowel diseases. Dtsch Med Wochenschr 2003; 128: 378-384

Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn`s disease: a defensin deficiency syndrome? Europ J Gastroenterol Hepatol 2003; 15: 627-634

Herrlinger K, Stange EF. Inflammatory bowel disease. Internist 2003; 44: 1151-1173

Schmid M, Fellermann K, Wehkamp J, Herrlinger K, Stange EF. The role of defensins in the pathogenesis of inflammatory bowel disease. Z Gastroenterol 2004; 42: 333-338

Herrlinger K, Stange EF. Inflammatory bowel disease – case report, diagnostics and therapy
Dtsch Med Wochenschr 2004; 129: 2243-2252

Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2:406-415

Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006; 24: 1403-12

Alscher DM, Herrlinger K, Stange EF. [Disturbances in volume and electrolytes with intestinal and kidney diseases] Internist 2006; 47: 110, 112-4, 115-20

De Boer NK, Reinisch W,. Teml A, van Bodegraven AA, Schwab M, Lucas M, Ochsenkuhn T, Petrisch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ; Dutch 6-TG working group. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006; 73: 25-31

Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases World J Gastroenterol 2006; 14: 4819-31

Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208

Hoffmann JC, Autschbach F, Bokemeyer B, Buhr HJ, Herrlinger K, Höhne W, Krieglstein C, Kruis W, Moser G, Preiss JC, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, Siegmund B, Stallmach A, Stange EF, Zeitz M. [Short version of the updated German S3 (level 3) guideline on diagnosis and treatment of Crohn's disease] Dtsch Med Wochenschr 2008; 133: 1924-1929

Herrlinger K, Stange EF. [Inflammatory bowel diseases--new therapeutic options] Med Klin 2008; 103: 90-101

Herrlinger K, Wittig B, Stange EF. Chronic inflammatory intestinal diseases. Pathophysiology and therapy. Internist 2009; 50:1229-46

Schreyer A, Ludwig D, Koletzko S, Hoffmann J, Preiss J, Zeitz M, Stange E, Herrlinger K.
Updated German S-3 guideline regarding the diagnosis of Crohn’s disease – Implementation of radiological modalities
RoFo 2009; 182:116-21

Schumann M, Herrlinger K, Zeitz M, Stange EF. New therapeutic approaches to special
diseases of the small intestine. Internist 2010; 51:730-6

Herrlinger K. Classification and management of upper gastrointestinal bleeding. Internist 2010; 51:1145-56

Herrlinger K, Stange EF. Treatment of Crohn's disease: step-up or top-down?.
Dtsch Med Wochenschr. 2010; 135:1694-8

Herrlinger KR. Differences between treatment guidelines--Germany. Dig Dis. 2013;31:357-9

Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease.
Expert Opin Biol Ther. 2014;14:455-66

Herrlinger K. [Inflammatory bowel disease: an overview]. Med Monatsschr Pharm. 2013;36:402-8

Herrlinger K, Fellermann K, Stange EF. [Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives]. Internist (Berl). 2014;55:906-17

Schmidt C, Herrlinger K, Siegmund B, Bokemeyer B, Schreiber S, Stallmach A; Kompetenznetz Darmerkrankungen. [Azathioprine in Crohn's disease therapy--guidance against the background of recent studies]. Z Gastroenterol. 2014;52:1423-30.


Book chapters

Medikamentöse Therapie des Morbus Crohn. Klaus Herrlinger und Eduard F. Stange, in: Chronisch entzündliche Darmerkrankungen: Morbus Crohn/Colitis ulcerosa.
Medpharm Scientific Publishers 2002

Azathioprin bei Morbus Crohn. Klaus Herrlinger und Eduard F. Stange, in Gross (Herausgeber): Azathioprin in der Gastroenterologie. UniMed-Verlag 2002

Therapiealternativen in der Immunsuppression bei Morbus Crohn: Mycophenolat-Mofetil und 6-Thioguanin. Klaus Herrlinger, in Dignass, Stein (Herausgeber): Chronisch entzündliche Darmerkrankungen - Stellenwert neuer therapeutischer Ansätze. Springer-Verlag 2002

Morbus Crohn. Klaus Herrlinger und Eduard F. Stange, in Schölmerich (Herausgeber): Medizinische Klinik in Therapie und Praxis. Springer-Verlag 2003

Konservative Therapie. Klaus Herrlinger und Eduard F. Stange, in Stange (Herausgeber): Colitis ulcerosa - Morbus Crohn. UniMed-Verlag 2004

Chronisch entzündliche Darmerkrankungen. K. Herrlinger, E.F. Stange, O. Schröder, J. Stein, H.J. Buhr, A.J. Kroesen, in Caspary, Mössner, Stein (Herausgeber): Therapie gastroenterologischer Krankheiten. Springer-Verlag 2005

Role of pharmacogenetics in the management of inflammatory bowel diseases. Herrlinger KR and Jewell DP, in Dignass, Rachmilewitz, Stange, Weinstock (Editors): Immunoregulation in Inflammatory Bowel Diseases – Current Understanding and Innovation. Springer-Verlag 2007

Morbus Crohn. K. Herrlinger, E.F. Stange, F. Fischer, H.P. Bruch, in Riemann, Fischbach, Galle, Mössner (Herausgeber): Gastroenterologie. Thieme 2008

Konservative Therapie. K. Herrlinger, in Stange (Herausgeber): Colitis ulcerosa – Morbus Crohn. Unimed-Verlag 2009, 4. Überarbeitete Auflage 2013

Inflammatory Bowel Diseases: Microbiota versus the barrier. E.F. Stange, A. Dignass, K. Fellermann, K. Herrlinger. Karger 2013

Morbus Crohn: konservative Therapie. K. Herrlinger, in Stange (Herausgeber): Entzündliche Darmerkrankungen. Schattauer Verlag 2015

Chronisch entzündliche Darmerkrankungen. K. Herrlinger, E.F. Stange, in Rationelle Diagnostik und Therapie in der Inneren Medizin. Urban und Fischer 2015